IBTK, inhibitor of Bruton tyrosine kinase, 25998

N. diseases: 33; N. variants: 0
Disease: B-Cell Lymphomas ×
Source: BEFREE ×
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.020 Biomarker group BEFREE Ibrutinib, an inhibitor of Bruton's tyrosine kinase, and venetoclax, an inhibitor of B-cell lymphoma 2 protein, have been approved for patients with chronic lymphocytic leukemia (CLL). 31141631 2019
CUI: C0079731
Disease: B-Cell Lymphomas
B-Cell Lymphomas 		0.020 AlteredExpression group BEFREE Ibrutinib (Imbruvica<sup>®</sup>) is an oral irreversible inhibitor of Bruton's tyrosine kinase, a B-cell receptor (BCR) signalling kinase expressed by various haematopoietic cells, B-cell lymphomas and leukaemias. 28105602 2017